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Impact of TREM2R47H variant on tau pathology–induced
gliosis and neurodegeneration
Maud Gratuze,1,2,3 Cheryl E.G. Leyns,1,2,3 Andrew D. Sauerbeck,1 Marie-Kim St-Pierre,4,5 Monica Xiong,1,2,3 Nayeon Kim,1,2,3 Javier
Remolina Serrano,1,2,3 Marie-Ève Tremblay,4,5 Terrance T. Kummer,1 Marco Colonna,2,3,6 Jason D. Ulrich,1,2,3
and David M. Holtzman1,2,3
Department of Neurology, 2Hope Center for Neurological Disorders, and 3Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA. 4Axe

1

Neurosciences, Centre de Recherche, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, Québec, Canada. 5Division of Medical Sciences, University of Victoria, Victoria, British
Columbia, Canada. 6Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.

Alzheimer’s disease (AD) is characterized by plaques containing amyloid-β (Aβ) and neurofibrillary tangles composed of
aggregated, hyperphosphorylated tau. Beyond tau and Aβ, evidence suggests that microglia play an important role in AD
pathogenesis. Rare variants in the microglia-expressed triggering receptor expressed on myeloid cells 2 (TREM2) gene
increase AD risk 2- to 4-fold. It is likely that these TREM2 variants increase AD risk by decreasing the response of microglia to
Aβ and its local toxicity. However, neocortical Aβ pathology occurs many years before neocortical tau pathology in AD. Thus,
it will be important to understand the role of TREM2 in the context of tauopathy. We investigated the impact of the ADassociated TREM2 variant (R47H) on tau-mediated neuropathology in the PS19 mouse model of tauopathy. We assessed PS19
mice expressing human TREM2CV (common variant) or human TREM2R47H. PS19-TREM2R47H mice had significantly attenuated
brain atrophy and synapse loss versus PS19-TREM2CV mice. Gene expression analyses and CD68 immunostaining revealed
attenuated microglial reactivity in PS19-TREM2R47H versus PS19-TREM2CV mice. There was also a decrease in phagocytosis of
postsynaptic elements by microglia expressing TREM2R47H in the PS19 mice and in human AD brains. These findings suggest
that impaired TREM2 signaling reduces microglia-mediated neurodegeneration in the setting of tauopathy.

Introduction

Alzheimer’s disease (AD) is the leading cause of dementia
worldwide and is the sixth leading cause of death in the United
States (1). The histopathological hallmarks of AD are extracellular amyloid plaques composed predominantly of the amyloid-β
(Aβ) peptide and neurofibrillary tangles (NFTs) within neurons
consisting of abnormally aggregated, hyperphosphorylated tau
protein (for reviews, refs. 2–4). Beyond tau and Aβ pathologies,
neuroinflammatory changes are present in AD and in primary
tauopathies (5), including alterations in the morphology, reactivity, distribution, and gene expression of microglia. The gene
expression changes that occur in microglia in the presence of
amyloid, tau, and other pathologies have been termed by some
as disease-associated microglia (DAM) (6) or the microglial neurodegenerative (MGnD) phenotype (7). In the DAM and MGnD
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phenotypes, there is a downregulation of so-called homeostatic microglial genes such as P2ry12, Tmem119, and Cx3cr1, while
there is an increase in the expression of several other genes such
as Apoe, Tyrobp, and Trem2 (6, 7). However, the exact contributions of innate immune activation to different types of pathologies and neurodegeneration are still not clear.
In the last decade, several novel genetic factors linked with
increased risk of AD have been identified thanks to new wholegenome sequencing and genome-wide association studies
(GWAS). Interestingly, many of these genetic risk factors
encode proteins involved in microglial function and inflammation including triggering receptor expressed on myeloid cells 2
(TREM2), CD33, CR1, ABCA7, SPI1, and SHIP1 (8). Particular
interest has been given to the microglia-expressed TREM2,
since rare variants in the TREM2 gene increase AD risk 2- to
4-fold (9, 10). TREM2 is a receptor that belongs to the immunoglobulin superfamily and is expressed on myeloid cells such
as microglia in the brain (11, 12). TREM2 signaling is associated with a number of downstream cellular processes including
proliferation and survival, suppression of Toll-like receptor–
induced inflammatory cytokine production, and facilitation of
metabolic ATP production (13). Several TREM2 variants have
been shown to impair, but not block, functional TREM2 signaling, resulting in the partial loss of function of the receptor. The
most common AD-associated TREM2 variant is rs75932628,
a single-nucleotide polymorphism encoding an arginine-tohistidine missense substitution at amino acid 47 (R47H)
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(9, 10). The TREM2R47H variant results in decreased TREM2 signaling upon ligand-induced stimulation (14, 15).
In order to better understand the role of TREM2 and ADassociated TREM2 variants in AD pathogenesis, several studies
have used models of AD pathology. In vivo studies in mouse models of amyloid deposition indicate a critical function for TREM2
in the clustering of microglia around plaques, plaque compaction, microglial proliferation, and phagocytosis, and in decreasing Aβ-induced neuritic dystrophy and tau seeding/spreading.
TREM2 knockout or expression of the TREM2R47H variant have
been shown to affect these phenotypes in the opposite direction
(14–18). These studies suggest that TREM2 signaling is protective
in decreasing Aβ-mediated local injury and in exacerbating the
Aβ-induced spreading of tau pathology. However, in AD and in
primary tauopathies, the accumulation of aggregated, hyperphosphorylated tau, and not Aβ, strongly correlates with local brain
atrophy and neuronal death. In AD, the accumulation of pathological forms of tau in the neocortex associated with atrophy and
cell death does not begin to occur until about 15–25 years after the
onset of Aβ deposition (19). The role of TREM2 and TREM2 variants linked to AD in the setting of tauopathy has been much less
studied. However, numerous clues in the literature suggest a link
between tau pathology and TREM2 in AD. In the cerebrospinal
fluid (CSF) of AD patients, soluble TREM2 has been shown to correlate with total and phosphorylated tau (p-tau, Thr181) levels (20,
21). Moreover, AD patients harboring the R47H variant of TREM2
display higher levels of both total tau and p-tau (Thr181) in CSF
compared with noncarriers (22, 23). Importantly, levels of p-tau in
the CSF correlate with tau pathology burden in the brain and with
neuronal loss and cognitive decline in AD patients (24). Previously, we reported a decrease in brain atrophy as well as attenuated
microgliosis in the brains of PS19 mice lacking TREM2 without a
significant change in tau pathology (25). In another study, Sayed
et al. also found that TREM2 knockout protected against taumediated microglial reactivity and atrophy (25), but that TREM2
haploinsufficiency was associated with elevated expression of
proinflammatory markers, exacerbated atrophy, and increased
tau pathology in PS19 mice (26). Finally, Bemiller et al. crossed
TREM2 knockout mice with mice expressing human tau (hTau
mice), a less aggressive mouse model of tauopathy, and identified
a decrease in microgliosis in TREM2-deficient hTau mice (27), as
observed in TREM2-deficient PS19 mice, but reported that complete deletion of TREM2 in hTau mice exacerbated tau pathology–related markers. These studies in primary tauopathy mouse
models suggest that TREM2 may play a dual role depending on the
disease stages; during early stages of tau pathology development
in the absence of neurodegeneration (e.g., hTau mice), decreased
TREM2 function might promote tau pathology, whereas the complete loss of TREM2 function in advanced stages (PS19 mice) of
the disease seems to protect from neurodegeneration. However,
no study to our knowledge has evaluated the impact of AD-associated TREM2 variants, such as TREM2R47H, in the setting of a model
of pure tauopathy, nor in a model that develops robust neurodegeneration as is seen in tau-related neurodegenerative diseases.
Given the emerging role for microglia in tau-mediated neuropathology, it is important to understand the role of AD-associated TREM2 variants that decrease, but do not eliminate, TREM2

signaling in the context of tauopathy and its associated neurodegeneration. Therefore, we investigated the impact of the most
prominent AD-associated TREM2 variant (R47H) on tau pathology and tau-mediated brain damage in the PS19 mouse model of tauopathy. PS19 mice were crossed with mice expressing
human TREM2 common variant, TREM2CV (PS19-T2CV mice), or
human TREM2R47H lacking the endogenous murine Trem2 gene
(PS19-T2R47H mice). We hypothesized that TREM2R47H would
result in a decreased microglial inflammatory response and would
protect against tau-dependent neurodegeneration. We observed
that PS19-T2R47H mice have reduced p-tau staining compared
with PS19-T2CV mice. Moreover, PS19-T2R47H mice have significantly attenuated brain atrophy and synapse loss compared with
PS19-T2CV mice. Gene expression analyses and CD68 immunostaining revealed attenuated microglial reactivity in PS19-T2R47H
versus PS19-T2CV mice. Importantly, a decrease in phagocytosis
of postsynaptic elements by microglia expressing TREM2R47H was
detected in PS19 mice and in postmortem human AD brains. Collectively, these findings suggest that reduced TREM2 signaling
reduces microglial conversion to a more proinflammatory, phagocytic state and is protective against neurodegeneration in the setting of advanced tauopathy.

Results

Effects of TREM2R47H on p-tau pathology. To determine whether
the presence of the R47H variant of TREM2 affects tau pathology and tau-related inflammation and neurodegeneration, we used
the PS19 tauopathy mouse model that overexpresses 1N4R hTau
containing the P301S mutation that causes a familial form of frontal temporal dementia. By 9 months of age, this model develops
strong tau hyperphosphorylation and aggregation, neurofibrillary
tangle deposition, and gliosis, as well as neuronal loss, brain atrophy, and loss of synaptic proteins in specific brain regions including the hippocampus, entorhinal cortex, piriform cortex, and
amygdala (28, 29). We crossed PS19 mice on a mouse TREM2-KO
background with bacterial artificial chromosome (BAC) transgenic mouse lines expressing either human TREM2CV or the ADassociated human variant TREM2R47H on a mouse TREM2-KO
background (15). Importantly, TREM2CV and TREM2R47H mice
express a similar level of TREM2 protein in the brain and expression of TREM2CV, but not TREM2R47H, rescues TREM2-dependent
phenotypes such as plaque-associated microgliosis (15).
At 3 months of age, before the overt onset of tau pathology, we
observed reduced staining with an antibody (AT8) specific for p-tau
phosphorylated on serine 202 and threonine 205 (p.Ser202/p.
Thr205), in the hippocampus (Supplemental Figure 1, B and D;
supplemental material available online with this article; https://
doi.org/10.1172/JCI138179DS1) and piriform cortex (Supplemental Figure 1, A and C) of PS19-T2R47H mice compared with PS19T2CV mice, although the change was only statistically significant in
the hippocampus. Staining with antibodies AT180 (p.Thr231) and
PG5 (p.Ser409) did not reveal any significant differences in p-tau
between PS19-T2R47H mice and PS19-T2CV mice in the piriform
cortex (Supplemental Figure 1, E, G, I, and K) or hippocampus
(Supplemental Figure 1, F, H, J, and L). To further examine tau and
p-tau levels in these mice, we performed a biochemical extraction
of hippocampal brain tissue and measured the concentration of
jci.org   Volume 130   Number 9   September 2020
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Figure 1. R47H variant of TREM2 attenuates tau pathology in 9-month-old PS19 mice. Representative images of p-tau staining (AT8, AT180, and PG5) in
the piriform cortex (A, E, and I) and hippocampus (B, F, and J) from 9-month-old PS19-T2CV and PS19-T2R47H mice. Scale bars: 1 mm. Quantification of the
percentage area covered by p-tau staining (antibodies AT8, AT180, and PG5) in the piriform cortex (C, G, and K) and hippocampus (D, H, and L). Data are
presented as the mean ± SEM. Significance was determined using an unpaired, 2-tailed Mann-Whitney test due to the nonparametric data set, except for
PG5 staining in the hippocampus where an unpaired, 2-tailed t test with Welch’s correction was used due to significantly different variances. *P < 0.05
(PS19-T2CV, n = 18 and PS19-T2R47H, n = 15/16). (M–O) ELISA results showing concentrations of p-tau (p.Ser202/p.Thr205 and p.Thr181) and total tau and
p-tau/total tau ratio in the hippocampus were quantified using a human tau–specific (hTau-specific) sandwich ELISA to measure p-tau (M), total tau (N),
and the p-tau/total tau ratio (O). The levels of p-tau and total tau (M and N) were normalized to total protein concentration. Data are presented as mean ±
SEM. Significance was determined by an unpaired, 2-tailed Student’s t test except for total tau where an unpaired, 2-tailed Mann-Whitney test was used
due to the nonparametric data set. *P < 0.05 (PS19-T2CV, n = 17 and PS19-T2R47H, n = 15).
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p-tau and total tau using a p-tau–specific (p.Ser202/p.Thr205
and p.Thr181) and hTau-specific ELISA. We observed no significant differences in p-tau (Supplemental Figure 1M) and tau levels
(Supplemental Figure 1N) or in the p-tau/tau ratio (Supplemental
Figure 1O) between PS19-T2R47H mice and PS19-T2CV mice. At 9
months of age, when substantial tau pathology had developed, we
again observed a significant decrease in hippocampal p-tau staining on serine 202/threonine 205 (Figure 1, B and D) as well as on
serine 409 (Figure 1, J and L) between PS19-T2R47H and PS19-T2CV
mice. There was no significant difference observed on these p-tau
epitopes in the piriform cortex (Figure 1, A, C, I, and K). Interestingly, staining p-tau on threonine 231 revealed less p-tau in the
piriform cortex of PS19-T2R47H mice compared with PS19-T2CV
mice (Figure 1, F and H), but no difference in the hippocampus
(Figure 1, E and G). Biochemical analysis of p-tau in hippocampal
brain tissue samples by ELISA revealed no significant differences
in p-tau level (Figure 1M) but increased total tau levels in PS19T2R47H mice compared with PS19-T2CV mice (Figure 1N), resulting
in a slight but not statistically significant (P = 0.0815) decrease in
the p-tau/tau ratio (Figure 1O) in PS19-T2R47H mice compared with
PS19-T2CV mice. These findings demonstrate that the R47H variant of TREM2 significantly attenuates increases in p-tau on some
tau sites mostly in the later stages of tau pathology in PS19 mice.
Interestingly, we (25) and others (27) did not observe lower p-tau
pathology in PS19 mice with TREM2 deleted compared with PS19
mice. New studies will be needed to better understand this difference, but we can hypothesize that the human TREM2CV assessed
in the present study has a slightly different impact on tau pathology than mouse TREM2 used in the previous studies.
Effects of TREM2R47H on brain atrophy. Because pathological
tau is directly linked to neurodegeneration, we next evaluated the
brain volume of these mice. As expected, no change in brain volume was detected between PS19-T2R47H and PS19-T2CV mice at 3
months of age, which is before when neurodegeneration has been
observed in this model (Supplemental Figure 2, A–E). At 9 months
of age when tau pathology is much more substantial and neurodegeneration is usually marked in specific brain regions in this model, the presence of TREM2R47H strongly attenuated brain atrophy
in PS19 mice compared with mice expressing TREM2CV (Figure 2,
A and E), similar to PS19 mice lacking TREM2 (25). More specifically, atrophy was significantly decreased by approximately 24%
in the hippocampus (Figure 2B) and by approximately 34% in the
piriform and entorhinal cortices (Figure 2D). When atrophy occurs
in hippocampal and cortical regions, there is concomitant enlargement of the lateral ventricles. TREM2R47H was also associated with
extensively reduced ventricular dilatation (~67%) in 9-month-old
PS19 mice (Figure 2C). Then, we estimated the neuronal loss
by measuring the thickness of the granule cell layer in the dentate gyrus and the pyramidal cell layer in the piriform cortex in
9-month-old mice. In accordance with changes observed in brain
volume, both the granule cell layer in the dentate gyrus (Figure
2, G and I) and pyramidal cell layer in the piriform cortex (Figure
2, F and H) were visibly and significantly thicker in PS19-T2R47H
compared with PS19-T2CV mice. This strikingly reduced neurodegeneration suggests an important role for TREM2 in regulating
tau-mediated brain atrophy, with the R47H variant of TREM2
being neuroprotective in the setting of tauopathy.
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Effects of TREM2R47H on microglial and astrocytic phenotypes.
Microglia are critical mediators of tau-dependent neurodegeneration (28, 30). Given that the TREM2R47H variant affects microglial function, and that PS19-T2R47H mice exhibited reduced neurodegeneration, we hypothesized that we would also observe
a state of reduced microglial reactivity as reflected by staining
with certain microglial markers. We assessed brain sections
with the myeloid immune cell marker ionized calcium–binding
adaptor molecule 1 (Iba1) to assess the overall microglial population. At 3 months of age, before the onset of overt tau pathology, there was no change in the surface area covered by microglia
in the piriform cortex (Supplemental Figure 3, A and C) or the
hippocampus (Supplemental Figure 3, B and D) between PS19T2R47H and PS19-T2CV mice. When we assessed microglial coverage in 9-month-old mice, we observed a marked decrease in
Iba1 staining in the piriform cortex (Figure 3, B and D) and the
hippocampus (Figure 3, C and E) of PS19-T2R47H in comparison
with PS19-T2CV mice. Consistent with these results, Iba1 gene
expression was reduced by approximately 32% in the cortex of
PS19-T2R47H versus PS19-T2CV mice (Figure 3A). Importantly,
reduced microgliosis induced by TREM2R47H in PS19 mice was
qualitatively similar to previous observations when TREM2 was
deleted in the same mouse model (25).
We next assessed microglial phenotypic and functional changes in the mice (Figure 4). CD68 (cluster of differentiation 68) labeling, a marker of phagolysosomal activity, was drastically reduced in
the piriform cortex (Figure 4C) and the hippocampus (Figure 4D) of
9-month-old PS19-T2R47H compared with PS19-T2CV mice. Strikingly, there was a decrease in CD68 staining of approximately 78% per
Iba1+ cell volume detected in PS19-T2R47H versus PS19-T2CV brains
(Figure 4, E and F), confirming a reduced activation state of PS19T2R47H microglia. We also assessed the microglial gene expression
profile in the cortex of 9-month-old PS19-T2R47H and PS19-T2CV mice
(Figure 4G). Consistent with lower CD68 staining in PS19-T2R47H
mice, all the DAM genes tested were downregulated in PS19-T2R47H
compared with PS19-T2CV mice such as Axl, Cst7, and Cd9. Interestingly, an increase in the expression of the homeostatic gene P2ry12
was observed in PS19-T2R47H mice, suggesting a more homeostatic
status of microglia compared with PS19-T2CV mice. On the other
hand, Cx3cr1 gene expression was decreased in PS19 mice expressing TREM2R47H, which may be due to a lower number of microglia
in these mice. Evaluation of several inflammatory cytokine genes
revealed a significant decrease in proinflammatory mediators such
as IL-1α, IL-1β, TNF-α, and TGF-β. IL-6 gene expression was not
altered by the AD-associated TREM2 variant in PS19 mice, as previously reported in PS19 knockout for TREM2 (25).
Another brain cell type, astrocytes, also plays an essential
role in neuroinflammation. It has been previously shown that
reactive microglia can induce astrogliosis through the production of cytokines as IL-1α and TNF-α that can promote neuronal death (32, 33). As previously observed in PS19 mice lacking
TREM2 (25), we found that glial fibrillary acidic protein (GFAP)
gene expression, a marker of reactive astrocytes, was decreased
in 9-month-old PS19-T2R47H compared with PS19-T2CV mice
(Supplemental Figure 4A). In addition, the GFAP signal was
drastically reduced in the piriform cortex (Supplemental Figure
4, B and D) of PS19-T2R47H compared with PS19-T2CV mice, but
jci.org   Volume 130   Number 9   September 2020
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Figure 2. R47H variant of TREM2 decreases neurodegeneration in 9-month-old PS19 mice. (A) Representative images of PS19-T2CV and PS19-T2R47H brain
sections stained with Sudan black at 9 months of age. Scale bars: 1 mm. (B–E) Quantification of the average volume of the hippocampus (B), ventricles
(C), entorhinal and piriform cortices (D), and half brain minus ventricle (E). (F–I) Thickness of the pyramidal layer of the piriform cortex (F and H) and the
granule cell layer of the dentate gyrus (DG) (G and I) in 9-month-old mice with cresyl violet staining. Data are presented as mean ± SEM. Significance was
determined by an unpaired, 2-tailed Student’s t test. *P < 0.05, **P < 0.01 (9-month-old: PS19-T2CV, n = 18/19 and PS19-T2R47H, n = 16).

not in the hippocampus (Supplemental Figure 4, E and C). Taken together, these data suggest that the R47H variant of TREM2
strongly reduced microglial activation and the concomitant
astrogliosis in the setting of tauopathy.
Effects of TREM2R47H on synapses. A recent study by Dejanovic
et al. reported a striking accumulation of complement C1q
4958
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in synapses of PS19 mice and AD patients (34). Synaptic C1q
accumulation correlated with augmented microglial engulfment of synapses in vivo and decline of synapse density in
vitro. Because we previously showed that C1q gene expression
can be modulated by the absence of TREM2 in PS19 mice, we
assessed how TREM2R47H affected protein and gene expression
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Figure 3. R47H variant of TREM2 decreases microgliosis in 9-monthold PS19 mice. (A) Expression of microglial marker Iba1 in the cortex of
9-month-old PS19-T2CV and PS19-T2R47H mice (PS19-T2CV, n = 11 and PS19T2R47H, n = 10). (B and C) Quantification of the percentage area covered by
Iba1 staining in the piriform cortex (B) and hippocampus (C) (PS19-T2CV,
n = 19 and PS19-T2R47H, n = 18). (D and E) Representative images of Iba1
staining in the piriform cortex (D) and hippocampus (E) from PS19-T2CV and
PS19-T2R47H mice. Scale bars: 0.5 mm. Data are presented as mean ± SEM.
Significance was determined using an unpaired, 2-tailed Mann-Whitney
test due to the nonparametric data set. *P < 0.05, **P < 0.01.

levels of C1q, as well as C1q+ synapses in PS19 mice. First, we
found that C1qa gene expression was reduced by approximately
60% in the cortex of 9-month-old PS19-T2R47H compared with
the PS19-T2CV mice (Figure 5C). Consistent with these findings,
C1q staining and confocal analysis revealed reduced C1q staining in PS19-T2R47H mice (Figure 5B). To evaluate C1q accumulation at putative synapses, we then assessed the number of puncta labeled with pre- and postsynaptic markers that were positive
for C1q. PSD-95+ puncta and synapsin+ puncta positive for C1q
were significantly decreased in PS19-T2R47H versus PS19-T2CV
mice (Figure 5, A, D, and E).
We next assessed whether the decrease in C1q-opsonized
synaptic-marker puncta and attenuated brain atrophy would
correspond to improved synaptic integrity in PS19-T2R47H mice.
We therefore quantified presynaptic (synapsin) and postsynaptic (PSD-95) marker puncta in PS19-T2R47H and PS19-T2CV mice
in the polymorphic layer of the piriform cortex (Figure 6A).
This revealed significantly more pre- and postsynaptic puncta
in PS19-T2R47H compared with PS19-T2CV mice (Figure 6, B and
C). As many such puncta are nonsynaptic (35, 36), we turned to
a more specific method of quantifying intact synaptic loci. Using
SEQUIN analysis (synaptic evaluation and quantification by
imaging of nanostructure) (36), a super-resolution imaging and
image analysis platform for quantifying synaptic loci, we detected significantly more intact synaptic loci in PS19-T2R47H versus

PS19-T2CV mice (Figure 6D). To better understand ultrastructural changes at synapses under these conditions, electron microscopy was undertaken in a small parallel cohort in the polymorphic layer of the piriform cortex. Synapses from PS19-T2CV mice
exhibited several dystrophic features, including swollen presynaptic elements, accumulation of enlarged autophagosomes, and
a reduced number of synaptic vesicles (Figure 6E). Moreover,
mitochondria often appeared swollen, a feature also seen with
hypoxia, and abundant dark dendritic spines, indicative of postsynaptic cellular stress, were visible (Figure 6E). In contrast,
electron microscopic images from PS19-T2R47H mice revealed
improved synaptic integrity with fewer autophagosomes, preserved mitochondrial ultrastructure, and less frequent dark dendrites/spines and axon terminals (Figure 6F). Importantly, these
results demonstrate that reduced brain atrophy in PS19-T2R47H
mice is associated with decreased synapses with dystrophic features and better preservation of pre- and postsynaptic elements.
Effects of TREM2R47H on microglial phagocytosis of synaptic elements. Regarding the role of TREM2 in microglial phagocytosis
(37, 38) and the fact that we observed strong reduction of CD68+
phagolysosomes in microglia of PS19-T2R47H versus PS19-T2CV
mice, we then hypothesized that impairment of microglial phagocytosis in 9-month-old PS19-T2R47H mice is responsible for the
decreased synapse loss. A previous study by Filipello et al. (39)
demonstrating that microglial TREM2 is required for synapse
elimination during the early stages of brain development strongly support this hypothesis. Costaining and confocal analysis for
the microglial phagolysosomal marker CD68 and the postsynaptic marker PSD-95 revealed significantly fewer PSD-95 puncta in CD68+ vesicles per microglia in the polymorphic layer of
the piriform cortex of 9-month-old PS19-T2R47H compared with
PS19-T2CV mice (Figure 7, A and B). Consistent with the higher content of synapses in 9-month-old PS19-T2R47H mice, these data show
an important role for TREM2 in synapse loss in PS19 mice that is
decreased by TREM2R47H in a pure tauopathy model.
Given these results, to assess the relevance of these findings in
the setting of tauopathy in human AD, we assessed whether the brains
of individuals who were TREM2-variant carriers who had AD exhibited similar reductions of postsynaptic puncta engulfed in CD68+
phagolysosomes compared with AD cases expressing TREM2CV. We
stained prefrontal cortex tissue from late-onset AD TREM2R47H and
TREM2R62H individuals and their case-matched controls for Iba1,
CD68, and PSD-95. R62H is another TREM2 variant associated with
an increased risk for AD (40, 41). Consistent with our mouse data, we
detected significantly fewer PSD-95 puncta engulfed in CD68+ vesicles per microglia in AD TREM2R47H and TREM2R62H brains compared
with AD brains with TREM2CV (Figure 7, C and D). The detection of
reduced synaptic phagocytosis by microglia expressing R47H or
R62H variants of TREM2 in AD cases confirms the defective synapse
elimination by microglia with TREM2 loss of function. Taken together, these data suggest that microglia expressing TREM2R47H phagocytose fewer synapses due to lower C1q accumulation in synapses,
resulting in neuroprotection in the setting of tauopathy.

Discussion

TREM2R47H has been associated with higher risk of developing
AD. Data from animal models and humans suggest that the
jci.org   Volume 130   Number 9   September 2020
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Figure 4. Reduced microglial activation and inflammatory gene expression in 9-month-old PS19-T2R47H versus PS19-T2CV mice. (A and B) Representative
images of CD68 staining from 9-month-old PS19-T2CV (A) and PS19-T2R47H (B) brains. (C and D) Quantification of the percentage area covered by CD68 staining in the piriform cortex (C) and hippocampus (D) (PS19-T2CV, n = 18 and PS19-T2R47H, n = 18). (E) Confocal images and 3D reconstruction of CD68+ structures
within Iba1+ microglia in PS19-T2CV and PS19-T2R47H. Scale bars: 10 μm. (F) Quantification of CD68+ structures per Iba1 volume (PS19-T2CV, n = 19 and
PS19-T2R47H, n = 15). Data are presented as mean ± SEM. Significance was determined using an unpaired, 2-tailed Mann-Whitney test due to the nonparametric data set. **P < 0.01, ***P < 0.001, ****P < 0.0001. (G) Heatmap analysis of microglial gene expression in 9-month-old PS19-T2CV and PS19-T2R47H
piriform cortex generated by hierarchical gene clustering based on genotypes. DAM genes, disease-associated microglia genes. For IL-1α, P2ry12, and TNF-α,
significance was determined by an unpaired, 2-tailed Student’s t test. For Apoe, Cst7, IL-1β, and IL-6, significance was determined using an unpaired, 2-tailed
Mann-Whitney test due to the nonparametric data set. For all other analyses, significance was determined by an unpaired, 2-tailed t test with Welch’s
correction due to significantly different variances. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (PS19-T2CV, n = 11 and PS19-T2R47H, n = 10).
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Figure 5. R47H variant of TREM2 lowers C1q+ synaptic markers in 9-month-old PS19 mice. (A) Representative images from confocal analysis of presynaptic
(synapsin in green) and postsynaptic (PSD-95 in red) markers, and C1q (purple) of 9-month-old PS19-T2CV and PS19-T2R47H piriform cortex. Scale bars: 3 μm.
Quantification of the percentage of C1q volume (B), C1q+ PSD-95 puncta number (D), and C1q+ synapsin puncta number (E) (PS19-T2CV, n = 20 and PS19-T2R47H,
n = 17). (C) Expression of cortical C1qa mRNA in 9-month-old PS19-T2CV and PS19-T2R47H mice (PS19-T2CV, n = 11 and PS19-T2R47H, n = 10). Data are presented as
mean ± SEM. Significance was determined using an unpaired, 2-tailed Mann-Whitney test due to the nonparametric data set. **P < 0.01, ***P < 0.001.

likely reason for this effect is that decreased TREM2 function
leads to a decreased microglial response to Aβ deposition,
increased Aβ-associated local neurotoxicity, and an exacerbation of Aβ-induced tau seeding and spreading (15, 42, 43).
However, during the time course of AD, Aβ aggregation and
accumulation in the neocortex occurs over a 15- to 25-year
period before symptom onset. Tau aggregation and pathology
development in the neocortex does not occur until just a few
years before the onset of cognitive decline. Thus, while TREM2
signaling may protect against Aβ-related changes in the brain,
the role of TREM2 signaling during the neocortical tau phase
(symptomatic phase) of AD and in primary tauopathies may
not be the same. This is critical to understand, as therapeutic
targeting of TREM2 may differ depending on the stage of the
disease. Our study unveils a role of TREM2 in the control of
tau-mediated synaptic elimination and neurodegeneration in
the setting of pure tauopathy that may also be relevant to the
neocortical tau phase of AD. Surprisingly, we demonstrated
that the AD-associated TREM2R47H variant strongly reduces the
development of brain atrophy, as well as synapse loss in PS19
mice. Importantly, in the presence of TREM2R47H, tau phosphorylation was decreased, suggesting that p-tau pathogenesis might be influenced by TREM2 function. Further analysis
revealed decreased microglial activation and reduced expression of several DAM genes in PS19-T2R47H mice. These results
indicate that TREM2 contributes to the microglial response
to tau pathology or tau-mediated impairment. Importantly, a
decrease in phagocytosis of postsynaptic elements by microglia expressing TREM2R47H was detected in PS19 mice and AD
patients and can, at least in part, explain the decrease in synaptic damage observed in PS19-T2R47H mice. Finally, we observed
that microglia expressing TREM2R47H phagocytose fewer synapses

due to lower C1q accumulation in synapses, resulting in neuroprotection in the setting of tauopathy.
Although the TREM2R47H variant has been associated with a
higher risk of developing AD, we observed delayed progression
of p-tau pathology and neurodegeneration in the hippocampus of
PS19-T2R47H mice. Surprisingly, in 2 previous studies of PS19 mice
with complete absence of TREM2, no change in tau pathology has
been reported (25, 26). We do not know the answer to why TREM2R47H
decreases some p-tau species at 9 months of age compared with
TREM2CV in PS19 mice, whereas TREM2 deletion did not have this
effect compared with mice expressing murine TREM2 (25). However, we can speculate that this dissimilarity results from the slightly
different age of the mice used between the 2 studies or because of the
difference between mouse and human TREM2. Indeed, in the Leyns
et al. study (25), the PS19 mice expressed mouse TREM2, which
may have a slightly different overall effect compared with human
TREM2CV used in this study. Unlike studies on PS19 mice, complete
deletion of TREM2 in hTau mice exacerbated tau phosphorylation
and insolubility (27). Despite the apparent confusion regarding the
impact of TREM2 on tau pathology, we hypothesized that reduced
tau pathology in PS19-T2R47H mice results from decreased microglial activation. Indeed, in a mouse model of tau propagation using an
injection of the AAV2/6-SYN1 promoter driving the expression of a
human P301L tau mutant into the brain, Asai et al. report that depleting microglia dramatically suppressed tau propagation (44). Moreover, microglial activation has been shown to correlate with a deficit in spatial memory and the spread of tau pathology in hTau mice
(45). Recently, our lab and others demonstrated that the progression of p-tau pathology is also driven by microglia in PS19 mice (28,
30). Moreover, the same study by Shi et al. (28) demonstrated that
microglia-mediated damage was the leading force driving neurodegeneration in a pure-tauopathy mouse model. Similarly, Leyns et al.
jci.org   Volume 130   Number 9   September 2020
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Figure 6. R47H variant of TREM2 reduces synapse loss in 9-month-old PS19 mice. (A) Representative images from confocal analysis of presynaptic
(synapsin in green) and postsynaptic (PSD-95 in red) markers of 9-month-old PS19-T2CV and PS19-T2R47H piriform cortex. Scale bars: 3 μm. (B–D) Quantification of puncta numbers from PSD-95 (B) and synapsin (C) staining, and SEQUIN quantification of synaptic loci (D). Data are presented as mean ± SEM. A
Mann-Whitney test was used to determine statistical significance for PSD-95 puncta due to the nonparametric data set. For all other graphs, significance
was determined by an unpaired, 2-tailed t test with Welch’s correction due to significantly different variances. **P < 0.01 (PS19-T2CV, n = 20 and PS19-T2R47H,
n = 17). (E and F) Electron microscopic images of the polymorphic layer of the piriform cortex from (E) a PS19-T2CV mouse and (F) a PS19-T2R47H mouse. Images
were obtained at ×9300 and ×6800 magnification, respectively, using an FEI Tecnai Spirit G2 transmission electron microscope. Purple = healthy terminal
axons, light blue = healthy dendritic spines, light pink = healthy mitochondria, yellow = dystrophic terminal axons, orange = altered mitochondria, red arrow =
dark dendritic spines, green arrow = dark dendrite. Asterisks indicate autophagosomes.
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Figure 7. R47H variant of TREM2 alters synapse engulfment by microglia in 9-month-old PS19 mice and human TREM2 variant carriers (R47H and
R62H). (A) Representative confocal images and relative 3D surface rendering showing volume reconstruction of CD68 (green) and engulfed PSD-95
puncta (red), detected within microglial CD68+ structures of 9-month-old PS19-T2CV and PS19-T2R47H piriform cortex. Scale bars: 5 μm. (B) Quantification
of engulfed PSD-95 puncta within CD68+ vesicles per microglia. Data are presented as mean ± SEM. Significance was determined using an unpaired,
2-tailed Mann-Whitney test due to the nonparametric data set. ***P < 0.001 (PS19-T2CV, n = 19 and PS19-T2R47H, n = 15). (C) Representative image from
confocal analysis of microglia (white), CD68 (green), and engulfed PSD-95 puncta (red), detected within microglial CD68+ structures in TREM2R47H (red
triangle) and TREM2R62H (yellow square) AD patients (AD-T2R47H/R62H) and case-matched TREM2CV AD controls. Scale bars: 5 μm. (D) Quantification of
engulfed PSD-95 puncta within CD68+ structures (arrowheads) per microglia. Data are presented as mean ± SEM. Significance determined by paired,
2-sided t test. *P < 0.05 (AD-T2CV, n = 9; AD-T2R47H, n = 5; and AD-T2R62H, n = 5).

and Sayed et al. previously reported that complete loss of TREM2
protects against tau-mediated brain atrophy as well as lower microgliosis (25, 26). Importantly, even though we observed decreased
tau pathology in PS19-T2R47H mice, the neuroprotective effect
by TREM2R47H characterized in this study is likely attributable to
reduced microglia-dependent neuronal damage rather than a direct
effect on p-tau pathology per se. Indeed, decreased tau pathology
in the piriform cortex has been observed only with p.Thr231, while
preserved brain volume, pyramidal layer thickness, and synaptic
integrity is reported in the piriform cortex of PS19-T2R47H mice as
well as a strong reduction of microgliosis. Moreover, Leyns et al.
previously reported a neuroprotection induced by TREM2 deletion in PS19 mice without a change in tau pathology but with lower microgliosis (25). Thus, diminished microgliosis resulting from
the R47H variant of TREM2 seems to explain the brain atrophy

attenuation in PS19 mice observed in this study. Because synapse
loss is well characterized in mouse models of tauopathies (29,
46–48), and TREM2 has been shown to play a key role in synaptic pruning during brain development (39), we then hypothesized
that TREM2 loss of function leads to lower brain atrophy in PS19
mice by inhibiting synaptic phagocytosis by microglia. Indeed, our
lab previously reported higher levels of PSD-95, a postsynaptic
marker, in PS19-TREM2-KO compared with PS19 mice (25). We
confirmed that PS19-T2R47H mice have strikingly more pre- and
postsynaptic markers, as well as better-maintained pre- and postsynaptic interactions compared with PS19-T2CV mice.
Although the TREM2R47H protective effect against tau-mediated brain atrophy and synapse loss seems clear in this study, the
possible mechanisms underlying this phenomenon are multiple.
First, chronic immune activation is known to result in high levels
jci.org   Volume 130   Number 9   September 2020
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of several proinflammatory cytokines such as TNF-α or IL-1β that
can induce synaptic excitotoxicity (49–52), and we show that PS19T2R47H mice have a robust reduction in the expression of TNF-α
and IL-1β, as well as several other proinflammatory cytokines compared with PS19-T2CV. Second, as previously mentioned, TREM2
is well known for its functions in promoting microglial cell survival (53) and in cellular phagocytosis (37, 54, 55). Filipello et al.
also determined that TREM2 is essential for microglia-mediated
synaptic refinement during the early stages of brain development
and that TREM2 deletion resulted in impaired synapse elimination
(39). Moreover, a recent study by Sheng at al. reported that TREM2
deficiency ameliorates synaptic deficits in 8-month-old APP/PS1
mice, an amyloid mouse model (56). In PS19-T2R47H mice, we confirmed the reduction of microglial phagocytic properties with fewer
CD68+ phagolysosomes within microglia. In addition, a decrease
in number of postsynaptic puncta engulfed in CD68+ vesicles was
observed not only in PS19-T2R47H mice, but also in AD patients harboring either the R47H mutation or the R62H mutation, another
AD-associated TREM2 variant (41, 57, 58). These data suggest that
partial loss of function induced by AD-associated TREM2 variants
might protect against aberrant synaptic phagocytosis by microglia
due to chronic inflammation. The impaired phagocytosis of synapses by microglia might also be due to lower C1q accumulation
in synapses. C1q, the initiating protein of the classical complement
cascade, is increased and associated with synapses before overt
amyloid plaque deposition in AD and inhibition of C1q reduces the
number of phagocytic microglia, as well as the extent of early synaptic loss in familial AD-mutant hAPP (J20) transgenic mice (59).
More recently, Dejanovic et al. (34) reported a striking accumulation of complement C1q in synapses of PS19 mice and AD patients.
Moreover, they demonstrated an association of synaptic C1q accumulation with augmented microglial engulfment of synapses and a
decrease in synapse density in vitro. Interestingly, we reported that
despite more synapses in PS19-T2R47H mice, there was dramatically
less C1q-opsonized synapsin and fewer PSD-95 puncta detected in
the brain of these mice in comparison with PS19-T2CV mice. This is
consistent with lower C1q accumulation in synapses of PS19-T2R47H
mice compromising the signal for microglia to engulfed them, preserving synaptic density. Importantly, a combination of all these
mechanisms resulting from the inhibition of a chronic inflammatory vicious circle remains conceivable here.
Obviously, an evident question emerges from this study: how
does TREM2R47H increase the risk of developing AD, but appear
protective against tau-mediated synapse loss? The answer might
be amyloid, tau, and time dependent. Recently, we have found
that TREM2 deficiency increases amyloid-induced tau spreading (42), which is a phase of AD pathogenesis that precedes the
tau-linked neurodegeneration phase of AD. In this study (42), we
showed that TREM2-KO or the AD-associated TREM2R47H variant
reduces microgliosis around Aβ plaques. Importantly, TREM2KO and the AD-associated TREM2R47H variant strongly promoted tau seeding and spreading in the form of neuritic plaque tau
aggregates. In addition, decreased plaque-associated microgliosis in these mice corresponded with higher periplaque Aβ42 accumulation and formation of neuritic dystrophy around plaques.
These findings demonstrate a critical role for TREM2 in microglia in inhibiting a key element of Aβ-facilitated tau pathology.
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Therefore, we hypothesize that AD-associated TREM2 variants
increase AD risk by promoting Aβ-mediated local toxicity and
facilitate tau seeding and spreading in the early pathological stages of the disease. However, in the later stages of the disease (i.e.,
symptomatic stage) and in primary tauopathies, when substantial
tau pathology has developed, AD-associated TREM2 variants
might slow down tau-mediated synapse loss in the brain through
reduction of synapse phagocytosis by microglia. It is important to
note that complete loss of function of TREM2 in humans results
in Nasu-Hakola disease characterized by cerebral degeneration
and white matter damage (60, 61). However, partial loss of function of TREM2 as seen with the TREM2R47H mutation in the heterozygous or homozygous condition is associated with increased
risk for AD (not with Nasu-Hakola disease) (9, 10, 62). Thus, it
may be that decreasing but not ablating TREM2 function during
the tau phase of neurodegeneration results in neuroprotection
not only in mouse models but also in humans.
Taken together, our data show that TREM2 plays a key role in
neurodegeneration in the context of tau pathology. Surprisingly,
the AD-associated TREM2R47H variant was strongly neuroprotective, probably because of decreased chronic inflammation and
decreased synaptic phagocytosis. While research on microglia
and TREM2 in AD has largely focused on TREM2 interactions
with Aβ pathology, this study suggests that TREM2 can directly
affect tau pathology and tau-mediated neurodegeneration in the
brain. This study raises new important questions about targeting
TREM2 as a therapeutic approach to treat AD. Indeed, stimulating the TREM2 pathway using antibodies or drugs is thought to
be a promising therapeutic strategy to treat or slow down AD progression. However, this study suggests that TREM2 exacerbates
tau-mediated neurodegeneration in the later stages of the disease when tau pathology is prominent. This study highlights the
complexity of using TREM2 as a target to treat AD or a primary
tauopathy. Moving forward, it will be important to identify and
establish the appropriate therapeutic window using close monitoring of neurodegenerative stage and inflammation-related AD
biomarkers to either stimulate or inhibit the TREM2 pathway
based on the disease and its stage. This should be possible with
the use of fluid- and imaging-based biomarkers. Importantly, this
study revealed for the first time to our knowledge that the ADassociated TREM2R47H variant is protective against tau pathology
and tau-mediated neurodegeneration.

Methods

Animals. PS19 transgenic mice expressing human P301S 1N4R
mutated tau driven by the PrP promoter were purchased from The
Jackson Laboratory (stock 008169). PS19 mice were backcrossed
and maintained on a mouse TREM2-KO background (T2KO). PS19T2KO were crossed with mice that had been engineered using BAC
technology to express either human TREM2CV or the AD-associated
TREM2R47H on a mouse T2KO background (15). These BAC transgenic mice carrying human TREM2 (common variant or R47H variant), TREML1, and TREML2 were backcrossed with T2KO mice
to yield mice that express either TREM2CV or TREM2R47H in the
absence of mouse TREM2. The use of BAC TREM2 models prohibited the ability to compare littermates with different genotypes in
this study. Because of the fact that male PS19 mice at different ages
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have greater tau pathology and neurodegeneration, and less variability than female mice (63, 64), only males were used for analysis
in this study. All mice were on the C57BL/6 background.
Sample collection. At time of death, mice were anesthetized
with i.p. pentobarbital (200 mg/kg). Blood samples were collected
in EDTA-treated tubes before cardiac perfusion with with 3 U/mL
heparin in cold Dulbecco’s PBS. Blood samples were spun down (10
minutes, 2000 g, 4°C), and blood plasma was collected. Brains were
carefully extracted and cut into 2 hemispheres. The left hemisphere
was collected for immunostaining and fixed in 4% paraformaldehyde
overnight before being transferred to 30% sucrose and stored at 4°C
until they were sectioned. Brains were cut coronally into 50-μm sections on a freezing sliding microtome (Leica, SM1020R) and stored
in cryoprotectant solution (0.2 M PBS, 15% sucrose, 33% ethylene
glycol) at –20°C until use. The right hemisphere was dissected to isolate the hippocampus and the cortex for biochemical analysis, and
the tissue was kept at –80°C until analyzed.
For electron microscopy, 3 mice per group were anesthetized
with i.p. pentobarbital (200 mg/kg) and perfused with 0.1% glutaraldehyde in 4% paraformaldehyde (65). Fifty-micrometer-thick coronal sections of the brain were cut in sodium phosphate buffer using
a vibratome (Vibratome series 1000 sectioning system) and stored
at –20°C in cryoprotectant until further processing (66).
Volumetric analysis of brains sections. Every sixth brain section
(300 μm between sections) starting rostrally at bregma –1.23 mm to
the dorsal end of the hippocampus at bregma –2.73 mm were mounted on slides and allowed to dry overnight for each mouse. The following day, mounted sections were stained with 0.1% Sudan black
in 70% ethanol at room temperature for 20 minutes, then washed
in 70% ethanol 3 times for 1 minute. The sections were washed in
Milli-Q water and coverslipped with Fluoromount (Southern Biotech). Slides were imaged with the NanoZoomer 2.0-HT system
(Hamamatsu Photonics) and areas of interest measured using the
NDP viewer software (Hamamatsu Photonics). The volume for each
region of interest was calculated using the following formula: volume = (summary of areas) × 0.3 mm.
Neuronal layer thickness measurement. Three sections (bregma –2.0,
–2.4, and –2.8 mm) per mouse were mounted and allowed to dry overnight. The following day, sections were stained in cresyl violet for 6 minutes at room temperature. The slices were then sequentially dehydrated
in increasing ethanol concentrations followed by xylene and coverslipped with Cytoseal 60 (Thermo Fisher Scientific, 8310-16). The thickness of the pyramidal cell layer of the piriform cortex and dentate gyrus
granular cell layer was measured by drawing a scale perpendicular to
the cell layer in all 3 slices and taking the average value for each mouse.
Brain extraction and tau and p-tau ELISA. Half of the hippocampus was weighed and homogenized using a pestle with 20 μL buffer/mg tissue (10 mM Tris-HCl pH 7.4, 0.8 M NaCl, 1 mM EDTA, 2
μM DTT, cOmplete and PhosStop [both Roche], and 10% sucrose).
Samples were centrifuged for 10 minutes at 10,000 g and 4°C.
Supernatant was removed and kept on ice while the pellet was re-homogenized in the same volume of buffer with a sonicator at 30%
amplitude, 1 second on/1 second off pulse, for 1 minute, and centrifuged for 10 minutes at 10,000 g and 4°C. The 2 supernatants were
pooled together and frozen until used. The concentration of tau and
p-tau was quantified by sandwich ELISA as previously described
(42) using Tau-5 (in-house antibody) as the coating antibody and
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human-specific biotinylated HT7 for detection for tau ELISA and
using HJ14.5 (in-house p.Thr181-tau antibody) as the coating antibody and human-specific biotinylated AT8 for detection for p-tau
ELISA. Briefly, 96-well half-area plates were coated with 20 μg/mL
of either HJ14.5 or Tau-5 antibody and incubated at 4°C overnight.
The next day, the plate was blocked in 3% BSA (RPI Corp.) in PBS
for 1 hour at 37°C. Next, peptide standards and samples were diluted in sample buffer (0.25% BSA/PBS, 1× protease inhibitor, 300
mM Tris pH 7.4, PBS), loaded onto the plate, and incubated at 4°C
overnight. On the third day, 0.3 μg/mL of biotinylated AT8 for p-tau
ELISA (Thermo Fisher Scientific, MN1020B) or biotinylated HT7
for tau ELISA (Thermo Fisher Scientific, MN1000B) was applied to
the plate for 1.5 hours at 37°C, and then Streptavidin-poly-HRP-40
(1:10,000 for tau and 1:6,000 for p-tau) (Fitzgerald) was applied for
1.5 hours at room temperature. TMB Superslow Substrate solution
(MilliporeSigma) was added and the plates were read at 650 nm on
a BioTek plate reader after developing for 30 minutes at room temperature. All samples were run in duplicate.
Immunohistochemistry. For staining microglia (Iba1, rabbit polyclonal, 1:5,000; Wako, 019-19741) and p-tau (AT8, mouse monoclonal, 1:500; Thermo Fisher Scientific, MN1020B — AT180, mouse
monoclonal, 1:500; Thermo Fisher Scientific, MN1040 — PG5,
mouse monoclonal, 1:500 [gift from Peter Davies, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New
York, USA]), sections were washed 3 times in TBS for 5 minutes and
blocked in 0.3% hydrogen peroxide for 10 minutes. After washing,
sections were blocked in 3% milk in TBS with 0.25% Triton X-100
(TBSX) for 30 minutes. Primary antibody was diluted in 3% milk/
TBSX, and the sections were incubated in the primary antibody overnight at 4°C. The next day, sections were washed and incubated with
secondary antibody diluted in 3% milk/TBSX for 1 hour. For AT8
staining, after washing, sections were incubated in ABC Elite solution (VectaStain, PK-6100) for 1 hour, prepared following the manufacturer’s instructions, followed by another washing step. For Iba1,
AT180, and PG5 staining, after washing, sections were incubated
with HRP-conjugated secondary antibodies for 1 hour at room temperature (1:500; Jackson Laboratory, 111-035-003). Sections were
developed in DAB solution (Vector Laboratories, SK4103), washed,
and mounted on slides. After drying overnight, the slides were dehydrated in increasing ethanol concentrations followed by xylene and
coverslipped with Cytoseal 60 (Thermo Fisher Scientific, 8310).
Slides were scanned on the NanoZoomer 2.0-HT system. Images
were further processed and quantified with the use of Fiji software
version 1.51. All areas were quantified in 2 to 3 sections (300 μm
apart from each other) per mouse.
Immunofluorescence. Immunofluorescence staining was performed as previously described (36). Briefly, free-floating tissue was
placed in 12-well plates with Netwell inserts (Corning) containing
PBS. Blocking solution and primary and secondary antibody mixtures were centrifuged at 17,000 g for 5 minutes just before use. Tissue was rinsed 3 times, 5 minutes each, in PBS followed by blocking
in 20% normal goat serum (NGS) in PBS for 1 hour at room temperature. Tissue was then incubated overnight at room temperature with
primary antibodies (CD68, rat monoclonal, 1:500; AbD SeroTec,
MCA1957), Iba1 (goat polyclonal, 1:5,000; Abcam, ab5076), PSD-95
(rabbit polyclonal, 1:200; Thermo Fisher Scientific, 51-6900), synapsin-1/2 (guinea pig polyclonal, 1:500; Synaptic Systems, 106004),
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and C1q (mouse monoclonal, 1:50; Abcam, ab71940) in 10% NGS
containing 0.3% Triton X-100 in PBS. The following day, sections
were rinsed 3 times, 5 minutes each, in PBS followed by incubation
in secondary antibodies (Thermo Fisher Scientific; 1;500) in 10%
NGS containing 0.3% Triton X-100 in PBS for 4 hours at room temperature. Sections were mounted, dried at room temperature, briefly
rinsed in distilled water, and then coverslipped. Mounting medium
(~150 μL/slide) was prepared the day of use by mixing Tris-MWL
4-88 (Electron Microscopy Sciences, 17977-150) with AF300 (Electron Microscopy Sciences, 17977-25) at a 9:1 ratio.
Image acquisition for immunofluorescence. Images were acquired
on an LSM 880 microscope with AiryScan detector (Zeiss). Quantification was performed using a semiautomated pipeline based on
MATLAB (MathWorks) and Imaris 9.3.1 software (Bitplane) as previously described (36). Spots were detected for each channel using
an x-y size of 0.2 μm, a z size of 0.6 μm, and automated background
subtraction. A 0.1-μm x-y and 0.3-μm z guard was applied to exclude
spots intersecting the edge of the image volume. Synaptic loci were
identified using custom MATLAB scripts from Sauerbeck (36) to
find the nearest neighbor based on the x-y-z centroid of the top 20%
brightest puncta. A cutoff of 270 nm pre-to-postsynaptic separation
was used to quantify synaptic loci for Figure 6 from the frequency
distribution of pre-to-postsynaptic separations. Complement labeling of synaptic loci was performed with Imaris 9.3.1 software by
creating a surface of C1q staining based on a threshold applied to all
images and by counting the number of pre- and postsynaptic spots
positive for this surface. Three images per mouse were obtained in
the polymorphic layer of the piriform cortex for this analysis.
Quantification of confocal images for Iba1 and CD68 was performed on a semiautomated platform using MATLAB and Imaris
9.3.1 software to create surfaces of each stain based on a threshold
applied to all images and colocalize Iba1 and CD68 surfaces to evaluate the volume of CD68+ vesicles within Iba1+ cells. For quantification
of the number of PSD-95 puncta engulfed in CD68+ phagolysosomes,
the PSD-95 puncta previously detected were automatically counted
within the CD68+ surface per microglia using Imaris 9.3.1 software.
Three to 5 microglia were imaged for each mouse or subject.
Immunofluorescence of human tissue. Paraffin-embedded 8-μm
sections were dewaxed in xylene for 6 minutes twice, followed
by rehydration descending ethanol to water (100% [twice], 95%,
90%, 70%, 30%, and 10% ethanol, followed by 100% water
[twice]). For antigen retrieval, slides were incubated for 45 minutes in citrate buffer, pH 6. Slides were incubated in 0.1% Sudan
black solution in 70% ethanol for 20 minutes to eliminate autofluorescence. After PBS washes, sections were blocked in 10% normal
donkey serum and 0.3% Triton X-100 for 1 hour and then placed
in primary antibodies overnight at 4°C in blocking solution: CD68
(mouse monoclonal, 1:100; DAKO, M0876), Iba1 (goat polyclonal, 1:500; Abcam, ab5076), and PSD-95 (rabbit polyclonal, 1:200,
Thermo Fisher Scientific, 51-6900). The following day, sections
were washed, placed in secondary antibodies for 2 hours (Thermo
Fisher Scientific; 1:500), and then washed again 3 times for 20 minutes each and mounted. Mounting medium was prepared the day
of use by mixing Tris-MWL 4-88 (Electron Microscopy Sciences,
17977- 150) with AF300 (Electron Microscopy Sciences, 17977-25)
at a 9:1 ratio followed by vortexing and bench-top centrifugation to
remove bubbles. High-precision 1.5H coverglasses were used for all
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experiments. Human samples were obtained from the Alzheimer’s
Disease Research Center at Washington University. TREM2R47H and
TREM2R62H AD cases were paired with TREM2CV AD cases matching
age, sex, and APOE genotype (Supplemental Table 1).
Gene expression. We extracted total RNA from mouse cortex
with the RNeasy Mini Kit (QIAGEN) and prepared cDNA with the
High-Capacity RNA-to-cDNA kit (Applied Biosystems), following manufacturers’ instructions. Gene expression analysis was
performed using microarray in collaboration with the Genome
Technology Access Core at Washington University. Using TaqMan
probes, the relative gene expression was quantitatively measured
using Fluidigm Biomark HD with integrated fluidic circuits.
Tissue preparation for electron microscopy. Three PS19-T2CV mice
and 2 PS19-T2R47H mice were used for electron microscopy. In each
animal, brain sections containing the polymorphic layer of the piriform cortex (bregma –1.67 mm to –1.91mm) were selected based
on the stereotaxic atlas of Paxinos and Franklin (67). The sections
were washed 3 times, 10 minutes each, with PBS, pH 7.4, and then
incubated 1 hour in a solution of equal volume of 3% potassium ferrocyanide in phosphate buffer (PB, 0.1 M, pH 7.4) and 4% aqueous
osmium tetroxide. Following washing 3 times, 5 minutes each in PBS,
tissues were incubated 20 minutes in a thiocarbohydrazide solution
and washed again 3 times, 5 minutes each in double-distilled water
(ddH2O). A 30-minute incubation of 2% osmium tetroxide (from
4% stock, diluted in ddH2O) was then performed. The brain sections were washed 3 times, 5 minutes each in ddH2O and dehydrated
with an increasing amount of ethanol (5-minute washes each): 35%
(twice), 50%, 70%, 80%, 90%, 100% (thrice). After dehydration in
ethanol, the sections were washed 3 times, 5 minutes each, in propylene oxide and were emerged overnight in Durcupan resin. The following day, tissues were placed between 2 ACLAR sheets (Electron
Microscopy Sciences) covered with a thin layer of resin and incubated 3 days at 55°C to polymerize.
Ultramicrotomy and transmission electron microscopy. The polymorphic layer of the piriform cortex was excised from the ACLAR
sheet with a razor blade and glued onto a resin block. The tissues
were then cut using an ultramicrotome (Leica Ultracut UC7), first
with a thickness of 300 nm to confirm the region of interest using
toluidine blue, and finally at a thickness of 70 nm. The ultrathin
sections were collected onto copper-mesh grids. The polymorphic
layer was imaged at 80 kV using a transmission electron microscope
(FEI Tecnai Spirit G2) equipped with a Hamamatsu ORCA-HR digital camera (10 MP). The user was blinded to the experimental conditions during imaging and ultrastructural interpretation. Images
of the synaptic neuropil were randomly acquired throughout the
region of interest so as to avoid bias. Sixteen to 20 nonoverlapping images at a magnification between ×6,800 and ×13,500 were
obtained per animal. Overall, between 575 μm2 and 729 μm2 of the
synaptic neuropil were imaged per animal.
Images were analyzed using the software ImageJ (NIH). For the
qualitative analysis of synaptic ultrastructure, the following parameters
were considered: the presence and size of autophagosomes; the presence of altered mitochondria; the presence of dark dendrites, dendritic spines, or axon terminals; and the presence of dystrophic synapses.
Dark cells (e.g., microglia, neurons) are characterized by ultrastructural signs of oxidative stress (endoplasmic reticulum dilation, condensation of the nucleoplasm and cytoplasm, altered mitochondria) (68,
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69) and have been seen previously in pathological conditions, such as
AD (70). Axon terminals were recognized by their inclusion of multiple
synaptic vesicles. Dendritic spines were recognized and differentiated
from dendrites by their size and presence of a postsynaptic density (71).
Dark synaptic elements were recognized by their electron-dense cytoplasm (72). Altered mitochondria were distinguished from normal ones
by their large increase in size and/or a disruption of their cristae and/
or outer membrane structure (73). Dystrophic synapses were defined
by the presence of autophagosomes, a reduced number of synaptic
vesicles, and a swollen shape (seen as an increase in size and/or electron-lucent content). Autophagosomes were recognized by their circular shape and delineating double membrane (74).
Statistics. Unless otherwise stated, all data are presented as
mean ± SEM. GraphPad Prism 8.0.0 was used to perform statistical
analyses. Gaussian distribution was evaluated using the D’Agostino-Pearson normality test. Statistical analysis was performed using
2-tailed Student’s unpaired t test under normal distribution. In case
of unequal variances, Welch’s correction was used with the Student’s
unpaired t test. If samples deviated from normal distribution, statistical analysis was performed using a Mann-Whitney test. For human
data, significance was determined by paired 2-tailed t test. P less
than 0.05 was considered significant: *P < 0.05, **P < 0.01, ***P <
0.001, and ****P < 0.0001 versus PS19-T2CV.
Study approval. All animal experimental protocols were approved
by the Animal Studies Committee at Washington University, St. Louis,
Missouri, USA.
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